ACP
KIN

Acuta Capital Partners’s Kindred Biosciences, Inc. KIN Stock Holding History

Acuta Capital Partners’s Portfolio KIN Stock Details KIN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-50,000
Closed -$170K – 58
2015
Q4 		$170K Hold
50,000
– – 0.08% 52
2015
Q3 		$260K Hold
50,000
– – 0.15% 58
2015
Q2 		$341K Sell
50,000
-25,000
-33% -$177K 0.21% 47
2015
Q1 		$536K Sell
75,000
-96,807
-56% -$667K 0.45% 42
2014
Q4 		$1.28M Buy
+171,807
New +$1.46M 0.87% 32

Other funds holding KIN

AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GCM
Gruss Capital Management New York $715M AUM 9.91% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $71.6B AUM 29.66% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Acuta Capital Partners's KIN Position: Q1 2016 in Review

Acuta Capital Partners sold out of Kindred Biosciences, Inc. (KIN) in Q1 2016, closing a stake of 50,000 shares — an estimated $170K sold.

Acuta Capital Partners first reported a position in KIN in Q4 2014 and held it in 5 quarters. The position peaked at $1.28M in Q4 2014. 44 funds tracked by Wall St. Rank hold KIN as of Q1 2016.

  • Acuta Capital Partners reported no remaining Kindred Biosciences, Inc. position as of Q1 2016 after selling out during the quarter.
  • Acuta Capital Partners sold 50,000 Kindred Biosciences, Inc. shares in Q1 2016, an estimated $170K.
  • Acuta Capital Partners first reported a position in Kindred Biosciences, Inc. in Q4 2014 and held it in 5 quarters.
  • Acuta Capital Partners's Kindred Biosciences, Inc. position peaked at $1.28M in Q4 2014.
  • 44 funds tracked by Wall St. Rank held Kindred Biosciences, Inc. as of Q1 2016.

Based on Acuta Capital Partners's 13F filing for Q1 2016, filed 13 May 2016.